Noradrenaline Bitartrate Injection
- Packing: 2 Ml Ampoule, 4 Ml Ampoule.
- Available Strength : 1 mg/ml, 2 Mg/Ml
Description
Product Description: Noradrenaline Bitartrate Injection is a sterile solution containing noradrenaline bitartrate, a sympathomimetic agent, for intravenous administration. It acts as a potent vasoconstrictor and cardiac stimulant, primarily used to increase blood pressure in cases of severe hypotension and shock.
Indications and Usage: Noradrenaline Bitartrate Injection is indicated for the treatment of acute hypotension and shock, including septic shock, cardiogenic shock, and hypotension during anesthesia. It is used to maintain blood pressure and organ perfusion in critically ill patients.
Dosage and Administration: The dosage of Noradrenaline Bitartrate Injection varies depending on the patient's age, weight, and clinical condition. It is administered intravenously through a central venous line to minimize the risk of extravasation. The infusion rate is titrated to achieve the desired hemodynamic response, typically starting at 0.05 to 0.2 mcg/kg/minute.
Dosage Forms and Strengths: Noradrenaline Bitartrate Injection is available as a sterile solution in vials for intravenous administration. It is commonly supplied in concentrations of 1 mg/mL or 4 mg/mL.
Contraindications: Noradrenaline Bitartrate Injection is contraindicated in patients with hypersensitivity to noradrenaline or any component of the formulation. It should not be used in patients with hypovolemia, ventricular tachycardia, or other conditions where increased blood pressure may be detrimental.
Warnings and Precautions: Use caution when administering Noradrenaline Bitartrate Injection to patients with hypertension, diabetes, hyperthyroidism, or other cardiovascular diseases. Rapid infusion or high doses may lead to severe hypertension, arrhythmias, or tissue necrosis. Avoid concurrent use with other sympathomimetic agents or monoamine oxidase inhibitors (MAOIs).
Adverse Reactions/Side Effects: Common adverse reactions associated with Noradrenaline Bitartrate Injection include hypertension, tachycardia, arrhythmias, and peripheral ischemia. Other side effects may include headache, nausea, vomiting, or anxiety. Serious adverse effects such as myocardial ischemia, pulmonary edema, or tissue necrosis may occur with prolonged use or excessive doses.
Drug Interactions: Noradrenaline Bitartrate Injection may interact with other sympathomimetic agents, vasopressors, or drugs affecting cardiac conduction, leading to additive cardiovascular effects. Concurrent use with MAOIs, tricyclic antidepressants, or ergot alkaloids may potentiate the effects of noradrenaline and increase the risk of adverse reactions.
Use In Specific Populations Description: Safety and efficacy of Noradrenaline Bitartrate Injection in pediatric patients, pregnant women, and nursing mothers have not been established. Use caution and consult with a healthcare professional before administering to individuals in these populations.
How Supplied/Storage and Handling: Noradrenaline Bitartrate Injection is supplied as a sterile solution in vials for intravenous administration. It should be stored at controlled room temperature (20°C to 25°C) away from light and moisture. Care should be taken to ensure proper storage and handling to maintain the integrity of the product. Unused portions should be discarded according to standard procedures for biohazardous waste.
